Depression (Primer On Series)

 

·                     Provides a comprehensive review of depression from diagnosis to treatment

·                     Includes sections on diagnosis and treatment considerations for special populations, such as youth, the elderly, and those with chronic or acute medical conditions

·                     Examines how research on biological markers may lead to precision medicine

·                     Includes both pharmacologic and non-pharmacologic treatment of depression

Description

Major depressive disorder (MDD) is a serious, debilitating, life-shortening illness that affects many persons of all ages and backgrounds. The lifetime risk for MDD is 7-12% for men and 20-25% for women (Kessler et al., 2003). MDD is a disabling disorder that costs the U.S. over $200 billion per year in direct and indirect costs (Greenberg et al., 2015), and is the leading cause of disability worldwide (WHO, 2018). Depression also has detrimental effects on all aspects of social functioning (e.g., self-care, social role, and family life, including household, marital, kinship, and parental roles). While there have been several treatments that are efficacious, many individuals suffering from depression experience life-long challenges due to the chronic and episodic nature of the disease. Identifying strategies to find the right treatments for the right patients is critical. Ongoing research has explored the importance of examining physiologic biomarkers, as well as clinical characteristics to gain a better understanding of subtypes of depression, which will lead to improved treatments and better outcomes.

This book provides an introduction to the etiology and pathophysiology of depression, common comorbidities and differential diagnoses, pharmacotherapy strategies, psychotherapeutic and neuromodulation interventions, novel and non-traditional treatment strategies, and considerations in special populations.

Table of Contents

 

1. Introduction and Overview
I. Etiology/Pathophysiology

2. Neurobiology

3. Genetic Risk Factors

4. Environmental and Social Risk Factors

5. Blood-based Biomarkers
II. Comorbidities and Differential Diagnoses

6. Anxiety Disorders

7. Bipolar Disorder

8. Suicidality

9. General Medical Conditions

10. General Medical Conditions, Metabolic Disorders
III. Pharmacotherapy for Depression

11. First line and combination therapeutics

12. Augmentation strategies

13. Rapid-acting antidepressants

14. Side Effects of Antidepressant

15. Strategies for targeting residual symptoms
IV. Psychotherapy and modalities of delivery for Depression

16. Cognitive Behavioral Therapy/Behavioral Activation

17. Behavioral Activation for Depression

18. Psychodynamic and Supportive Psychotherapy

19. ECT/TMS
V. Novel, Non-Traditional Treatment Strategies for Depression

20. Exercise as a treatment for depression

21. Therapeutic Mindfulness For Relapse Prophylaxis in Unipolar Depression

22. Probiotics and Neutraceuticals

23. Chronobiological Treatments: Sleep and Light Therapies
VI. Special Populations in Depression

24. Children and Adolescents

25. Elderly Patients

26. Pregnant and Postpartum

27. Depression Following Mild Traumatic Brain Injury

28. Treatment in Primary Care
VII. MISCELLANEOUS

29. Future Directions: Precision Medicine and Biosignatures